(23 days)
Not Found
Not Found
No
The device description and performance studies describe a simple lateral flow immunoassay that relies on antibody-antigen binding and visual interpretation of colored bands, with no mention of computational analysis or algorithms.
No
The device is a diagnostic test (a pregnancy test), not a therapeutic device. It identifies hCG to aid in pregnancy determination, but does not treat or manage a condition.
Yes
This device is intended for the qualitative identification of hCG in urine to aid in the early determination of pregnancy, which is a diagnostic purpose.
No
The device description clearly outlines a physical test strip that utilizes chemical reactions and capillary action to detect hCG in urine. This involves hardware components (the test strip itself) and is not solely software.
Yes, this device is an IVD (In Vitro Diagnostic).
Here's why:
- Intended Use: The intended use explicitly states "qualitative identification of hCG (human Chorionic Gonadotropin) in urine to aid in the early determination of pregnancy." This is a diagnostic purpose performed on a biological specimen (urine) in vitro (outside the body).
- Device Description: The description details how the test works by detecting a specific analyte (hCG) in a biological sample (urine) using antibodies and observing a reaction (colored bands). This is characteristic of an in vitro diagnostic test.
- Performance Studies: The document describes a clinical evaluation comparing the device to another commercially available test using urine specimens. This type of study is conducted to demonstrate the performance of an IVD.
N/A
Intended Use / Indications for Use
AimStep™ Pregnancy is intended for the qualitative identification of hCG (human Chorionic Gonadotropin) in urine to aid in the early determination of pregnancy. This test is for professional use.
Product codes
JHI
Device Description
AimStep Pregnancy is intended for the qualitative identification of hCG (human Chorionic Gonadotropin) in urine to aid in the early determination of pregnancy. The test utilizes a combination of monoclonal and polyclonal antibodies to selectively detect elevated levels of hCG. The assay is conducted by dipping the test strip into urine and observing for the formation of colored bands. The specimen migrates via capillary action along the membrane to react with the colored conjugate. Positive specimens react with the specific antibody-hCG-colored conjugate and form a colored band on the Specimen portion of the membrane. Absence of this colored band suggests a negative result. To serve as a procedural control, a colored band at the Control Zone will always appear regardless of the presence or absence of hCG.
Mentions image processing
Not Found
Mentions AI, DNN, or ML
Not Found
Input Imaging Modality
Not Found
Anatomical Site
Not Found
Indicated Patient Age Range
Not Found
Intended User / Care Setting
professional use
Description of the training set, sample size, data source, and annotation protocol
Not Found
Description of the test set, sample size, data source, and annotation protocol
A multi-center clinical evaluation was conducted comparing the results obtained using AimStep™ Pregnancy and another commercially available test. The study included 148 urine specimens tested with both assays. The following results were found:
AimStep™: 64 Positive Results, 84 Negative Results
Commercially Available Test: 64 Positive Results, 84 Negative Results
Summary of Performance Studies (study type, sample size, AUC, MRMC, standalone performance, key results)
A multi-center clinical evaluation was conducted comparing the results obtained using AimStep™ Pregnancy and another commercially available test. The study included 148 urine specimens tested with both assays. AimStep™ Pregnancy showed a 100% concordance with the other commercially available test. AimStep™ Pregnancy detects hCG concentrations of 20 mIU/ml and greater. The test has been standardized to the World Health Organization Third International Standard. The addition of hLH (300 mIU/ml), hFSH (1000 ulU/ml), and hTSH (1000 ulU/ml) to negative (0 mIU/ml hCG) and positive (20 mIU/ml hCG) urine showed no cross-reactivity.
Key Metrics (Sensitivity, Specificity, PPV, NPV, etc.)
100% concordance with the other commercially available test. Detects hCG concentrations of 20 mIU/ml and greater. No cross-reactivity with hLH (300 mIU/ml), hFSH (1000 ulU/ml), and hTSH (1000 ulU/ml).
Predicate Device(s)
Not Found
Reference Device(s)
Not Found
Predetermined Change Control Plan (PCCP) - All Relevant Information
Not Found
§ 862.1155 Human chorionic gonadotropin (HCG) test system.
(a)
Human chorionic gonadotropin (HCG) test system intended for the early detection of pregnancy —(1)Identification. A human chorionic gonadotropin (HCG) test system is a device intended for the early detection of pregnancy is intended to measure HCG, a placental hormone, in plasma or urine.(2)
Classification. Class II.(b)
Human chorionic gonadotropin (HCG) test system intended for any uses other than early detection of pregnancy —(1)Identification. A human chorionic goadotropin (HCG) test system is a device intended for any uses other than early detection of pregnancy (such as an aid in the diagnosis, prognosis, and management of treatment of persons with certain tumors or carcinomas) is intended to measure HCG, a placental hormone, in plasma or urine.(2)
Classification. Class III.(3)
Date PMA or notice of completion of a PDP is required. As of the enactment date of the amendments, May 28, 1976, an approval under section 515 of the act is required before the device described in paragraph (b)(1) may be commercially distributed. See § 862.3.
0
"Summary of Safety & Effectiveness"
MAR - 6 1998
AimStep Pregnancy is intended for the qualitative identification of hCG (human Chorionic Gonadotropin) in urine to aid in the early determination of pregnancy. The test utilizes a combination of monoclonal and polyclonal antibodies to selectively detect elevated levels of hCG. The assay is conducted by dipping the test strip into urine and observing for the formation of colored bands. The specimen migrates via capillary action along the membrane to react with the colored conjugate. Positive specimens react with the specific antibody-hCG-colored conjugate and form a colored band on the Specimen portion of the membrane. Absence of this colored band suggests a negative result. To serve as a procedural control, a colored band at the Control Zone will always appear regardless of the presence or absence of hCG.
A multi-center clinical evaluation was conducted comparing the results obtained using AimStep™ Pregnancy and another commercially available test. The study included 148 urine specimens tested with both assays. The following results were found:
| Positive Results | Negative Results | |
|---|---|---|
| AimStep™ | 64 | 84 |
| Commercially | ||
| Available Test | 64 | 84 |
AimStep™ Pregnancy showed a 100% concordance with the other commercially available test.
AimStep™ Pregnancy detects hCG concentrations of 20 mIU/ml and greater. The test has been standardized to the World Health Organization Third International Standard. The addition of hLH (300 mIU/ml), hFSH (1000 mIU/ml), and hTSH (1000 ulU/ml) to negative (0 mIU/ml hCG) and positive (20 mIU/ml hCG) urine showed no cross-reactivity.
Whate O'Conne
Martin O'Connor, Regulatory Affairs
Martin O'Connor, Regul Germaine Laboratories. In 4203 Gardendale Center, Suite 230
2-9-98
Date
Premarket Notification 510(k) Number
Page 1 of 17
1
Image /page/1/Picture/1 description: The image shows the logo for the Department of Health & Human Services USA. The logo consists of a circle with the text "DEPARTMENT OF HEALTH & HUMAN SERVICES USA" around the perimeter. Inside the circle is an image of an eagle.
Food and Drug Administration 2098 Gaither Road Rockville MD 20850
MAR - 6 1998
Martin O'Connor . General Manager Germaine Laboratories, Inc. 4203 Gardenale Center Suite 230 San Antonio, Texas 78229
Re : K980531 AimStep™ Pregnancy Regulatory Class: II Product Code: JHI February 9, 1998 Dated: Received: February 11, 1998
Dear Mr. O'Connor:
We have reviewed your Section 510(k) notification of intent to market the device referenced above and we have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.
If your device is classified (see above) into either class II (Special Controls) or class III (Premarket Approval), it may be subject to such additional controls. Existing major regulations affecting your device can be found in the Code of Federal Requlations, Title 21, Parts 800 to 895. A substantially equivalent determination assumes compliance with the Current Good Manufacturing Practice requirements, as set forth in the Quality System Regulation (QS) for Medical Devices: General regulation (21 CFR Part 820) and that, through periodic QS inspections, the Food and Drug Administration (FDA) will verify such assumptions. Failure to comply with the GMP regulation may result in requlatory In addition, FDA may publish further announcements action. concerning your device in the Federal Register. Please note: this response to your premarket notification submission does not affect any obligation you might have under sections 531 through 542 of the Act for devices under the Electronic Product Radiation Control provisions, or other Federal laws or regulations.
2
Page 2
Under the Clinical Laboratory Improvement Amendments of 1988 (CLIA-88), this device may require a CLIA complexity categorization. To determine if it does, you should contact the Centers for Disease Control and Prevention (CDC) at (770) 488-7655.
This letter will allow you to begin marketing your device as described in your 510 (k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.
If you desire specific advice for your device on our labeling regulation (21 CFR Part 801 and additionally 809.10 for in vitro diagnostic devices), please contact the Office of Compliance at (301) 594-4588. Additionally, for questions on the promotion and advertising of your device, please contact the Office of Compliance at (301) 594-4639. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR 807.97). Other general information on your responsibilities under the Act may be obtained from the Division of Small Manufacturers Assistance at its toll-free number (800) 638-2041 or (301) 443-6597 or at its internet address "http://www.fda.gov/cdrh/dsmamain.html".
Sincerely yours,
Steven Bitman
Steven I. Gutman, M.D., M.B.A. Director Division of Clinical Laboratory Devices Office of Device Evaluation Center for Devices and Radiological Health
Enclosure
3
Indications For Use
510(k) Number: K980631
Device Name: AimStep™ Pregnancy
"Indications For Use" -
AimStep™ Pregnancy is intended for the qualitative identification of hCG (human Chorionic Gonadotropin) in urine to aid in the early determination of pregnancy. This test is for professional use.
(Please do not write below this point)
Concurrence of CDRH, Office of Device Evaluation (ODE)
(Division Sign-Off)
Division of Clinical Laboratory Devices
Prescription Use
(per 21 CFR 801.109)
or
Over-The-Counter-Use